6results about How to "No obvious toxicity" patented technology

The application discloses a small cell lung cancer treatment target and application thereof. The application proves, through experimental research, that UBE2S has a specific high expression feature in small cell lung cancer (SCLC). The application of UBE2S as a target in development or design of a drug for treating SCLC is disclosed, and the application of a UBE2S targeted inhibitor in preparation of a drug for treating SCLC is disclosed. Odetiglucan can be used as a polysaccharide small molecule compound and can selectively inhibit SCLC cells with high expression of UBE2S. The application provides a new target and a drug research and development direction for precise treatment of SCLC.

This invention discloses a periodontitis-targeted antibacterial supramolecular material, its preparation method, and its application. It belongs to the field of catalyst technology. The preparation method of the periodontitis-targeted antibacterial supramolecular material includes the following steps: dissolving 2,5-dihydroxyterephthalic acid and tetrakis(4-aminophenyl)porphyrin in a first solvent, adding a first catalyst to react, and obtaining a DHA-TAPP COF skeleton; dispersing the DHA-TAPP COF skeleton in a second solvent, adding 3-bromopropyltrimethylammonium bromide and a second catalyst to react, and obtaining Q-COF; dispersing Q-COF in a third solvent, mixing it with H2PtCl6 solution, and then placing it under light conditions to obtain Pt-Q-COF; dispersing Pt-Q-COF in a buffer solution, adding pyruvate oxidase for adsorption treatment, and obtaining POx-Pt-Q-COF. This invention achieves a synergistic effect of "targeted enrichment - dual ROS generation - closed-loop H2O2 supply" through material structure design and functional unit integration, thereby improving the clearance efficiency of periodontal pathogens while ensuring biocompatibility.

The present application relates to the technical field of biological medicine, and particularly relates to a luteolin and chrysin complex and application thereof in improving insulin resistance drugs, wherein the molar ratio of luteolin to chrysin in the complex is 1:1. The present application discloses, for the first time, the synergistic hypoglycemic mechanism of the complex with the specific ratio through in vitro enzymatic experiments, insulin resistance cell models, and verification of transcriptomics, metabolomics and molecular biology. The complex can not only synergistically inhibit alpha-amylase and alpha-glucosidase activities to reduce postprandial blood glucose, but also improve insulin resistance in multiple dimensions and multiple targets by synergistically regulating the PI3K-AKT signaling pathway, inhibiting IL-17 / NF-kappa B-mediated inflammatory response and regulating fat decomposition and anabolism. The complex provided by the present application has the advantages of significant synergistic effect, clear mechanism of action, high safety and the like, and provides a new choice for developing a novel natural source hypoglycemic drug.

The invention discloses an application of Harman alkali in the aspect of preparing a Pseudomonas plecoglossicida inhibitor, and is characterized in that the Harman alkali is applied in the aspect of preparing a medicine for preventing and / or treating aquatic animal infectious diseases caused by Pseudomonas plecoglossicida. The invention further provides application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating aquatic animal plecoglossus altivelis pseudomonas infection, application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating plecoglossus altivelis liver injury, application of a plecoglossus altivelis immunoregulation medicine and application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of an aquaculture feed additive. The method has the advantages that the survival rate of aquatic animals can be remarkably increased in a Pseudomonas plecoglossicida infection model, the bacterial load in immune tissues such as blood, liver, spleen, head and kidney and the like is reduced, and liver and spleen tissue pathological injury and cell apoptosis caused by infection are relieved; meanwhile, harmine can improve biochemical and antioxidant indexes of infection-related serum, and has no obvious toxicity to fish-derived cells within a certain concentration range.

The application discloses injectable long-acting collagen and a preparation method and application thereof, and belongs to the technical field of collagen preparation. The application solves the problems of rapid degradation and insufficient mechanical property of collagen after injection into the body, and the problem of inability to have biological safety, good biological activity and injectability. The long-acting collagen is prepared by taking methoxypolyethylene glycol active ester and collagen as raw materials. Amide reaction is caused between the methoxypolyethylene glycol active ester and lysine residues on the collagen, hydrophilic PEG is introduced on the surface of the collagen, a hydration layer is formed, biological enzymes are hindered from contacting the collagen, collagen degradation is delayed, and the single-arm structure of the methoxypolyethylene glycol active ester can avoid product agglomeration and abnormal viscosity caused by excessive cross-linking. The long-acting collagen has a long retention time in the body, has no obvious cytotoxicity, has high biological safety, and maintains cell proliferation, migration and adhesion activity and biological repair functions.

This invention relates to a selenium-modified gold nanocomplex encapsulated in ginger exosomes, its preparation method, and its applications, belonging to the fields of biomedical technology and nanomedicine formulations. The complex is assembled from L-selenomethylselenocysteine-modified gold nanoparticles as the core and ginger exosomes as the shell. The preparation method includes: first, preparing selenium-modified gold nanoparticles via a one-step reduction method, then mixing and incubating them with ginger exosomes in a specific ratio to obtain the GE-Se-Au complex. This invention's complex directly inhibits tumor cell proliferation by downregulating the p-ERK / c-Myc pathway, while simultaneously inducing macrophage M1 polarization to remodel the immune microenvironment, achieving a synergistic effect between chemotherapy and immunotherapy. In vitro and in vivo experiments show that this complex has a significant inhibitory effect on drug-resistant non-small cell lung cancer, with extremely low toxicity to normal cells and major organs, demonstrating good biocompatibility. This invention features a simple preparation process and strong targeting, providing a new strategy for overcoming drug resistance in lung cancer clinically.